

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



深圳市海王英特龍生物技術股份有限公司  
**SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED\***  
*(a joint stock limited company incorporated in the People's Republic of China)*  
**(Stock Code: 8329)**

**APPOINTMENT OF EXECUTIVE DIRECTOR  
AND  
RETIREMENT OF NON-EXECUTIVE DIRECTOR**

**APPOINTMENT OF EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of Shenzhen Neptunus Interlong Bio-technique Company Limited (the “**Company**”) is pleased to announce that Mr. Zhang Xiao Guang (“**Mr. Zhang**”) has been appointed as an executive Director with effect from 25 June 2023.

The biographical details of Mr. Zhang are set out below:

**Mr. Zhang Xiao Guang** (張曉光), aged 57, graduated from China FAW Group Workers College (中國第一汽車集團職工大學), majoring in mechanical and electrical automation. Mr. Zhang has been working in the pharmaceutical industry for over 20 years and officially joined the Shenzhen Neptunus Group Company Limited (深圳海王集團股份有限公司) in 2009. He has served as the sales manager, the provincial manager of Shanxi and Jilin provinces, the sales director of the north China region, and the deputy national sales supervisor and deputy national sales general manager of Shenzhen Neptunus Changjian Pharmaceutical Co., Ltd. (“**Neptunus Changjian**”). Mr. Zhang is currently the general manager of Neptunus Changjian. Mr. Zhang has extensive experience in sales management and has won multiple awards in the industry, including the Outstanding Management Team Award and Excellent Manager Award of the OTC Sales Department of Neptunus Changjian.

A service agreement will be entered into between the Company and Mr. Zhang for a term of three years commencing from 25 June 2023 and ending on 24 June 2026. His appointment may be terminated by either party giving not less than three months' written notice to the other. He is entitled to receive a remuneration of RMB100,000 per annum (which is tax inclusive and to be paid on a monthly basis with the Company being responsible for withholding personal income tax). This remuneration has been determined by the Board with reference to his duties, responsibilities and the performance and results of the Company, and shall be reviewed by the remuneration committee from time to time. Within the permitted scope regulated by relevant laws, regulations and policies of the PRC, any reasonable and necessary expenses (including but not limited to travel expenses) paid by Mr. Zhang for the provision of director's service to the Company or due to the execution of work relevant to matters for the Company's operation will be borne by the Company.

As at the date of this announcement, Mr. Zhang was interested within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) in 430,000 shares of Shenzhen Neptunus Bio-engineering Co., Ltd., the Company's controlling shareholder as defined in GEM Listing Rules, which in turn held directly and indirectly the beneficial interest in approximately 73.51% of the entire issued share capital of the Company.

As at the date of this announcement, save as disclosed above, Mr. Zhang (i) has not held any directorship in the past three years in other public companies of which their securities are listed on any securities market in Hong Kong or overseas, (ii) does not hold any other positions with the Company and any other members of the Group, and (iii) does not have any relationship with any Directors, supervisors, senior management, substantial or controlling shareholders (as defined in the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited ("**GEM Listing Rules**") of the Company.

Save as disclosed above, there is no other matter that needs to be brought to the attention of the shareholders of the Company and there is no other information requiring to be disclosed pursuant to Rule 17.50(2)(h) to (v) of the GEM Listing Rules in connection with the appointment of Mr. Zhang.

The Board would like to take this opportunity to welcome Mr. Zhang to the Board.

## **RETIREMENT OF NON-EXECUTIVE DIRECTOR**

The Board announces that Mr. Shen Da Kai ("**Mr. Shen**") did not seek for re-election at the annual general meeting of the Company due to work arrangement. Therefore, the term of office of Mr. Shen will expire on 24 June 2023 and he will retire from his office as a non-executive Director. Mr. Shen has confirmed that he has no disagreement with the Board and the Company and there is no matter which needs to be brought to the attention of the shareholders of the Company in relation to his retirement.

The Board takes this opportunity to express its sincere gratitude to Mr. Shen for his valuable contribution to the Company during his tenure of office.

By Order of the Board  
**Shenzhen Neptunus Interlong Bio-technique Company Limited\***  
**Zhang Feng**  
*Chairman*

Shenzhen, the PRC, 21 June 2023

*As at the date of this announcement, the executive Directors are Mr. Zhang Feng and Mr. Huang Jian Bo; the non-executive Directors are Mr. Zhang Yi Fei, Ms. Yu Lin, Mr. Shen Da Kai and Mr. Jin Rui; and the independent non-executive Directors are Mr. Yick Wing Fat, Simon, Mr. Poon Ka Yeung and Mr. Zhang Jian Zhou.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief (i) the information contained in this announcement is accurate and complete in all material aspects and not misleading or deceptive; and (ii) there are no other matters the omission of which would make any statement in this announcement or this announcement misleading.*

*This announcement will remain on the “Latest Company Announcements” page of the GEM website at [www.hkgem.com](http://www.hkgem.com) for at least 7 days from its date of publication and on the Company’s website at [www.interlong.com](http://www.interlong.com).*

\* For identification purpose only